title: The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication.
abstract: OBJECTIVE
  Fluid retention is a phenomenon associated with taxoids. The principal objective of this study was to investigate the pathophysiological mechanism of docetaxel-induced fluid retention in advanced cancer patients.
  
  
  METHODS
  Docetaxel was administered as a 1 h intravenous infusion every 3 weeks, for at least 4-6 consecutive cycles, to patients with advanced breast (n = 21) or ovarian (n = 3) carcinoma, who had received previous chemotherapy, 21 for advanced disease. Phase II clinical trials have shown that 5 day corticosteroid comedication, starting 1 day before docetaxel infusion, significantly reduces the incidence and severity of fluid retention. This prophylactic corticosteroid regimen is currently recommended for patients receiving docetaxel but was not permitted in this study because of its possible interference with the underlying pathophysiology of the fluid retention.
  
  
  RESULTS
  Fluid retention occurred in 21 of the 24 patients but was mainly mild to moderate, with only five patients experiencing severe fluid retention. Eighteen patients received symptomatic flavonoid treatment, commonly prescribed after the last cycle. Specific investigations for fluid retention confirmed a relationship between cumulative docetaxel dose and development of fluid retention. Capillary filtration test analysis showed a two-step process for fluid retention generation, with progressive congestion of the interstitial space by proteins and water starting between the second and the fourth cycle, followed by insufficient lymphatic drainage.
  
  
  CONCLUSIONS
  A vascular protector such as micronized diosmine hesperidine with recommended corticosteroid premedication and benzopyrones may be useful in preventing and treating docetaxel-induced fluid retention.
authors.affiliation: Hôtel-Dieu, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Béhar
authors.forename: E
authors.initials: E
authors.lastname: Pujade-Lauraine
authors.forename: A
authors.initials: A
authors.lastname: Maurel
authors.forename: M D
authors.initials: MD
authors.lastname: Brun
authors.forename: F F
authors.initials: FF
authors.lastname: Chauvin
authors.forename: F
authors.initials: F
authors.lastname: Feuilhade de Chauvin
authors.forename: D
authors.initials: D
authors.lastname: Oulid-Aissa
authors.forename: D
authors.initials: D
authors.lastname: Hille
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000503:physiopathology; D000305:Adrenal Cortex Hormones / Q000494:pharmacology; D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004487:Edema / Q000139:chemically induced* / Q000503:physiopathology; D005260:Female; D005419:Flavonoids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D008208:Lymphatic System / Q000187:drug effects; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D043823:Taxoids; D014882:Water-Electrolyte Balance / Q000187:drug effects
chemical_list: D000305:Adrenal Cortex Hormones; D000972:Antineoplastic Agents, Phytogenic; D005419:Flavonoids; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel